Dermatologists from the Mount Sinai Health System performed 726 skin cancer screenings at the Aspen Ideas Festival (AIF), identifying 18 possible melanomas and 46 potential non-melanoma skin cancers (basal cell and squamous cell abnormalities). These potential diagnoses must be confirmed with additional testing.
Conferences
Immunotherapy in Melanoma: What Does the Future Hold?
Melanoma has been at the forefront of the immuno-oncology revolution, a trend that continued at the 2015 ASCO Annual Meeting.
Interpreting PD-L1 Status Among Key Melanoma Topics at ASCO
Key areas in the treatment of melanoma discussed at the 2015 ASCO Annual Meeting included selecting appropriate immunotherapy regimens based on PD-L1 status and improving surgical practices. OncLive sat down with Jason J. Luke, MD, assistant professor of Medicine at University of Chicago Medicine, to provide deeper insight on both topics.
Moffitt Analysis Nivolumab Safety In Melanoma Patients
During the the 2015 American Society of Clinical Oncology Annual Meeting in Chicago, Jeffrey S. Weber, M.D., Ph.D., director of the Donald A. Adam Comprehensive Melanoma Research Center at Moffitt Cancer Center presented the results from a retrospective analysis on the safety of nivolumab in 4 ongoing phase I-III studies in patients with melanoma. This monoclonal antibody was found to be an important therapeutic agent and was able to improve the survival rates of patients with melanoma.